MedEdTalks Oncology is an accredited educational podcast for providers to learn more about treating patients with Oncology diseases/disorders. Discover all content and topics by visiting mededtalks.com.
Case Studies on the Use of IO in NSCLC With Drs. Jeffrey Kern and Laurie Carr
4 Jan 2023
Updates on the Use of Neoadjuvant and Adjuvant IO in Patients With NSCLC With Drs. Laurie Carr and Heather Wakelee
4 Jan 2023
Updates in IO for Advanced NSCLC – Options for First-line Treatment and Management of Progressive Disease With Drs. Laurie Carr and Heather Wakelee
4 Jan 2023
NSCLC: Updates in Testing and Interpreting Results – Focus on IO With Drs. Laurie Carr and David Ross Camidge
4 Jan 2023
NSCLC: Optimizing Care Coordination – Through the Patient and Caregiver’s Eyes
4 Jan 2023
Lung Cancer Advances and Challenges During a Pandemic – Where Do We Go From Here? With Drs. Jeffrey Kern and Charu Aggarwal
11 May 2021
Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy With Drs. Howard Kaufman and Anna Pavlick
Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.
11 May 2021
Mechanisms of Oncolytic Viral Therapy With Drs. Howard Kaufman and Kevin Harrington
Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.
11 May 2021
Overview of Oncolytic Viral Therapy – Focus on Melanoma With Drs. Howard Kaufman and Dmitriy Zamarin
Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma.
10 May 2021
Oncolytic Viral Therapy – A Look at the Latest Evidence With Drs. Howard Kaufman and Ann Silk
Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.
11 Nov 2019
Updates in Newly-Diagnosed PTCL
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in the management of newly diagnosed PTCL.
To earn CME credit, follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-updates-in-newly-diagnosed-ptcl
Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_updates-in-newlydiagnosed-ptcl.pdf
11 Nov 2019
Antibody-Drug Conjugates in PTCL
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast expert clinicians will discuss antibody-drug conjugates in PTCL.
To earn CME Credit, please follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-antibody-drug-conjugates-in-ptcl
Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_antibodydrug-conjugates-in-ptcl.pdf
7 Oct 2019
Options for Relapsed/Refractory PTCL
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss options for managing relapsed/refractory PTCL.
To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-options-for-relapsed-refractory-ptcl
25 Sept 2019
Updates in Diagnosis of PTCL and the Role of CD30
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in diagnosis of PTCL and the role of CD30.
To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-updates-in-diagnosis-of-ptcl-and-the-role-of-cd30
Contact MedEdTalks - Oncology
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of MedEdTalks - Oncology?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
